Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled study of BI 3000202 in moderate to severe systemic lupus erythematosus
PACTR202609920803264Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing BI 3000202 with Placebo (2 arms). Primary endpoints: Non-flat dose response curve based on SRI-4 response at Week 32 and Treatment effect of BI 3000202 dose regimens versus placebo based on SRI-4 at Week 32. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
BI 3000202
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on PACTR202609920803264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609920803264.